Popular on Amzeal
- Aquia Inc. Selected to Support the U.S. Air Force and DoD's Platform One CNAP Team on its Mission to Modernize Federal Government's Cybersecurity - 143
- Aquia Inc. Announces Support of Platform One's Iron Bank in an Effort to Centralize and Standardize Application Hardening Throughout the DoD - 123
- San Diego Patch Company sets up www.MauiStrong.help site to help raise money for the residents of Maui - 104
- Fake Tech Job Claims, Do Not Always Mean Fake Technology! Say Developers At Uafab Technologies
- UVify at the 2023 Commercial UAV Expo: Leading the Way with World-Dominating Swarm Light Show Technologies and Advanced Autonomous Drone Platforms
- Prince Oakleyski Eurasia will release a film for God's sake. The movie title is "Monotheism and Devils", directed by Prince Oak Oakleyski
- Former DEI Officer Poised to Resume Work in Civil Rights Space After Addressing False Allegations
- Entrinsik's User Conference, Entrinsicon 2023, Returns to Raleigh!
- Trendsetting@Work Launches M-PACT™ Investment Round; CEO Challenges Norms
- Greenville, SC Economic Development Leader Mark Farris Stepping Down
Similar on Amzeal
- Leaders share experiences with industrial engineering institute on its 75th anniversary
- National Brain Tumor Society to Launch Campaigns Elevating the Necessity of Clinical Trials and Biomarker Testing Access
- Diffractive optical network enables multispectral quantitative phase imaging in a snapshot
- Universal transformations of spatially varying polarization fields
- Worlds largest wind farm begins construction in the UK
- The Ohio State University to Offer an Online, Asynchronous Corrosion Short Course Fall 2023
- Amerigo Scientific Introduces Water Purification Systems for Life Science Research
- August Deadline Approaching for the 2023 Oil & Gas Cleantech Challenge
- Orbex Awarded "Best CFD Broker Asia" at the Mumbai Money Expo 2023
- Universal Linear Processing of Spatially Incoherent Light Through Diffractive Optical Networks
Phoreus Biotech launches BAPtofect®-25 peptide transfection reagent
Amzeal News/10516410
The new product offers a superior alternative to industry-leading, lipid-based reagents
OLATHE, Kan. - Amzeal -- Phoreus Biotech, a leading provider of next-generation peptide nanocarriers, announced today they've added a new product to their portfolio of proprietary transfection reagents. The new BAPtofect-25 for general cell transfection now allows researchers to work with a large variety of cell lines to compliment the company's previous offerings for use in insect cell lines.
"Researchers have been stuck for too long with using lipid-based transfection reagents that can be very cytotoxic," said Michael Coe, CSO, Phoreus Biotech. "We're pleased to present a new option that has a number of advantages over the leading reagents available today."
Cell transfection is the process of introducing DNA, RNA, or other genetic material into cells to modify or activate those cells. It is a critical step in many areas of research, from gene therapy to vaccine development. Phoreus Biotech has been a provider of transfection reagents for more than four years, and they continue to expand their portfolio with innovative products like BAPtofect-25. This new product allows researchers to work with numerous difficult-to-transfect cell lines, making it an essential tool for any lab working in this field.
More on Amzeal News
The lipid-based transfection reagents that have long served as the industry standard suffer from several serious limitations. While liposomal-based carriers can achieve high transfection rates, there are multiple issues associated with their use in research. Lipid-based carriers tend to be unstable, resulting in a premature breakdown that releases their cargo before reaching the intended destination. Additionally, liposomes can sometimes form aggregates and precipitate out of solution or clump together instead of remaining evenly dispersed throughout the solution. Due to their lack of stability and inherent toxicity to cells, there remains a strong need for better transfection reagent options.
BAPtofect-25 provides extremely high transfection rates, compared to the leading liposomal-based carriers, with expression in nearly all cells. The product also maintains excellent cell viability with virtually no cellular toxicity. Users typically see diffuse transfection in cells, rather than the pinpoint transfection of other reagents. BAPtofect-25 also offers the distinct advantage of being able to move seamlessly from in-vitro research to in-vivo applications, unlike the lipid transfection reagents which differ significantly from the lipid nanoparticles used in modern mRNA vaccines. Phoreus nanocarriers have now been referenced in more than 25 research publications for effective in vitro and in vivo nanodelivery.
More on Amzeal News
"We are fully committed to providing researchers with the best possible tools to improve the important work they conduct every day," said Steve Schram, CEO, Phoreus Biotech. "BAPtofect-25 is another example of that commitment."
About Phoreus Biotech
Phoreus Biotech is an Olathe, KS-based life science company and is the provider of three proprietary nanocarrier platforms with the capacity to revolutionize human, animal, plant, and environmental health. Their Branched Amphipathic Peptide Capsules (BAPC®), Corralling Amphipathic Peptide Capsules (CAPC®), and Amphipathic Peptide Capsules (APC®) offer substantially increased efficacy in the creation and delivery of vaccines, cancer therapies, antibiotics, diagnostics, and biopesticides.
"Researchers have been stuck for too long with using lipid-based transfection reagents that can be very cytotoxic," said Michael Coe, CSO, Phoreus Biotech. "We're pleased to present a new option that has a number of advantages over the leading reagents available today."
Cell transfection is the process of introducing DNA, RNA, or other genetic material into cells to modify or activate those cells. It is a critical step in many areas of research, from gene therapy to vaccine development. Phoreus Biotech has been a provider of transfection reagents for more than four years, and they continue to expand their portfolio with innovative products like BAPtofect-25. This new product allows researchers to work with numerous difficult-to-transfect cell lines, making it an essential tool for any lab working in this field.
More on Amzeal News
- Actionstep Acquires North American Legal Accounting Platform Soluno
- RelyMD Bolsters its Telehealth Platform with Mental Health Services via CuraLinc Partnership
- Multiply Unveils Comprehensive White Paper on ChatGPT & Generative AI in Personal Finance
- Calvetta Phair, Founder of new recruitment application – ReferAll, Announce Acceptance Google for Startups, Black Founder Exchange Program
- Handle Chatbot Elevates Customer Interaction with the Introduction of Generative AI Capabilities
The lipid-based transfection reagents that have long served as the industry standard suffer from several serious limitations. While liposomal-based carriers can achieve high transfection rates, there are multiple issues associated with their use in research. Lipid-based carriers tend to be unstable, resulting in a premature breakdown that releases their cargo before reaching the intended destination. Additionally, liposomes can sometimes form aggregates and precipitate out of solution or clump together instead of remaining evenly dispersed throughout the solution. Due to their lack of stability and inherent toxicity to cells, there remains a strong need for better transfection reagent options.
BAPtofect-25 provides extremely high transfection rates, compared to the leading liposomal-based carriers, with expression in nearly all cells. The product also maintains excellent cell viability with virtually no cellular toxicity. Users typically see diffuse transfection in cells, rather than the pinpoint transfection of other reagents. BAPtofect-25 also offers the distinct advantage of being able to move seamlessly from in-vitro research to in-vivo applications, unlike the lipid transfection reagents which differ significantly from the lipid nanoparticles used in modern mRNA vaccines. Phoreus nanocarriers have now been referenced in more than 25 research publications for effective in vitro and in vivo nanodelivery.
More on Amzeal News
- Live Good Inc. Celebrates Diversity and Unity: A Beacon of Progress in the Spirit of Crissy Field, Angel Island and the Buffalo Soldiers
- AMERICAST Provides PreCast Pads to Charge Stations
- Woman-Owned Technology Studio in Austin Celebrates Milestone With Initiative to Empower Girls
- Sheila Stubbs Taylor of Detroit music royalty is "Chasing" on new single
- Sidow Sobrino Announces 12th Album, "Seminal"
"We are fully committed to providing researchers with the best possible tools to improve the important work they conduct every day," said Steve Schram, CEO, Phoreus Biotech. "BAPtofect-25 is another example of that commitment."
About Phoreus Biotech
Phoreus Biotech is an Olathe, KS-based life science company and is the provider of three proprietary nanocarrier platforms with the capacity to revolutionize human, animal, plant, and environmental health. Their Branched Amphipathic Peptide Capsules (BAPC®), Corralling Amphipathic Peptide Capsules (CAPC®), and Amphipathic Peptide Capsules (APC®) offer substantially increased efficacy in the creation and delivery of vaccines, cancer therapies, antibiotics, diagnostics, and biopesticides.
Source: Phoreus Biotech
Filed Under: Science
0 Comments
Latest on Amzeal News
- Flint's Got Talent Returns To Showcase Creativity In Community
- Autonomous eVTOLs $25 Billion Market by 2030
- Global Life Settlement Exchange: Selling a Life Insurance Policy Might be a Better Option Than Letting it Lapse or Surrendering it
- Jiritsu Raises $10.2 Million in Funding to Revolutionize Verifiable Compute
- Heartland Soccer Set to Host Sold Out Midwest All Boys Tournament this Weekend
- Material Capital Partners Completes Exit of The Preserve at Sweetwater, Expands BFR Pipeline in the Southeast
- Tobu Railway Launches Its Latest Model "Spacia X" Express Train with 40% Reduced CO2 Emissions Compared with the Previous Spacia Fleet
- Axiros Launches a New Release of their USP Agent - AXACT 2023.4
- North Carolina Entrepreneur Awarded 2023 Small Business Advocate of the Year By NSBA
- Instant Gourmet Coffee With The Authentic Taste & Refreshing Smell Of Cafe De Olla, Infused With The Wonderful Health Benefits Of Superfoods
- Modern Requirements to Present at Info-Tech Research Group's LIVE Conference 2023
- Berlin Packaging Fires Female Executive Following Complaints of Discrimination
- Falcomm selected for 2023 TechCrunch Startup Battlefield 200
- Patton Acquires Tone Commander
- Customer Agility Framework™ soft launch
- Refonte Infini Announces Official Launch with Debut of Proprietary Crypto Trading Bot
- New Kickstarter Campaign - 7 Exclusive Novels from Ray Keating
- Moolwan releases 10 new Home Decor Items to help customers decorate their homes into opulent masterpieces
- City of Fairfax triples access to public restrooms with innovative high tech solution
- Cloud9 Insight Announces Strategic Partnership with ClickDimensions to Launch Innovative PowerPack for SMBs